| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Guido Grassi | Q61303944 |
| Massimo Volpe | Q37829227 | ||
| P2093 | author name string | Enrico Agabiti Rosei | |
| Rhian M Touyz | |||
| Claudio Borghi | |||
| Carmine Savoia | |||
| P2860 | cites work | Phased whole-genome genetic risk in a family quartet using a major allele reference sequence | Q21144940 |
| Pharmacometabolomics reveals racial differences in response to atenolol treatment | Q21559685 | ||
| Evidence Supporting a Systolic Blood Pressure Goal of Less Than 150 mm Hg in Patients Aged 60 Years or Older: The Minority View | Q22305305 | ||
| Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure | Q22306384 | ||
| Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 | ||
| RNA-Seq: a revolutionary tool for transcriptomics | Q24596169 | ||
| A small-cell lung cancer genome with complex signatures of tobacco exposure | Q24600510 | ||
| Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study | Q45107143 | ||
| A functional variant of NEDD4L is associated with hypertension, antihypertensive response, and orthostatic hypotension. | Q45918466 | ||
| Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial | Q46047741 | ||
| NICE hypertension guideline 2011: evidence based evolution | Q46134939 | ||
| Personalized medicine: Time for one-person trials | Q46268988 | ||
| The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem | Q46570585 | ||
| Time to Reassess Blood-Pressure Goals | Q47598037 | ||
| Management of hypertension in adults: the 2013 French Society of Hypertension guidelines | Q47624090 | ||
| Shattuck Lecture. The hypertension paradox--more uncontrolled disease despite improved therapy. | Q48547775 | ||
| The burden of adult hypertension in the United States 1999 to 2000: a rising tide. | Q50143429 | ||
| Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. | Q50934595 | ||
| Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to β-blocker therapy in hypertension. | Q51496434 | ||
| Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. | Q51922378 | ||
| Association of common polymorphisms in β1-adrenergic receptor with antihypertensive response to carvedilol. | Q54189411 | ||
| beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. | Q54594315 | ||
| The current role of next-generation DNA sequencing in routine care of patients with hereditary cardiovascular conditions: a viewpoint paper of the European Society of Cardiology working group on myocardial and pericardial diseases and members of the | Q38407538 | ||
| The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension | Q38455833 | ||
| Clinical Trials of Precision Medicine through Molecular Profiling: Focus on Breast Cancer | Q38493885 | ||
| A critical appraisal of the guidelines from France, the UK, Europe and the USA for the management of hypertension in adults | Q38538291 | ||
| Systems biology and the future of medicine | Q38647215 | ||
| Use of Biomarkers in the Evaluation and Treatment of Hypertensive Patients | Q38843567 | ||
| Estimates of global and regional premature cardiovascular mortality in 2025. | Q38959964 | ||
| Conceptual Foundations of Systems Biology Explaining Complex Cardiac Diseases | Q39147941 | ||
| Prevalence and Control of Hypertension in Different Macro-Areas in Italy: Analysis of a Large Database by the General Practice | Q39310495 | ||
| Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm | Q39386631 | ||
| Executive Summary: Heart Disease and Stroke Statistics--2016 Update: A Report From the American Heart Association | Q40061255 | ||
| Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension | Q40569218 | ||
| Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol | Q40576862 | ||
| Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study | Q40664994 | ||
| The SCX/IMAC enrichment approach for global phosphorylation analysis by mass spectrometry | Q42122474 | ||
| Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients | Q43425314 | ||
| Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. | Q43816619 | ||
| Blood pressure and cardiovascular disease in the Asia Pacific region | Q43835108 | ||
| Stroke mortality and trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure. | Q44036462 | ||
| Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics | Q44226354 | ||
| Next-generation sequencing data interpretation: enhancing reproducibility and accessibility | Q44853811 | ||
| Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension | Q44990922 | ||
| Erratum to: Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues | Q56965911 | ||
| Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial | Q57274347 | ||
| Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles | Q68669670 | ||
| Lessons learned combining N-of-1 trials to assess fibromyalgia therapies | Q79170066 | ||
| P38 MAPK inhibitors suppress biomarkers of hypertension end-organ damage, osteopontin and plasminogen activator inhibitor-1 | Q80168179 | ||
| A functional variant of the NEDD4L gene is associated with beneficial treatment response with β-blockers and diuretics in hypertensive patients | Q82317917 | ||
| An improved quantitative mass spectrometry analysis of tumor specific mutant proteins at high sensitivity | Q84141226 | ||
| Genomics is not enough | Q85056192 | ||
| Resistant hypertension? Assessment of adherence by toxicological urine analysis | Q85931476 | ||
| Genetic variation in NEDD4L, an epithelial sodium channel regulator, is associated with cardiovascular disease and cardiovascular death | Q86858190 | ||
| Clinical assessment incorporating a personal genome | Q24612653 | ||
| Identification of high-confidence somatic mutations in whole genome sequence of formalin-fixed breast cancer specimens | Q24622594 | ||
| Rare independent mutations in renal salt handling genes contribute to blood pressure variation | Q24627187 | ||
| A comprehensive catalogue of somatic mutations from a human cancer genome | Q24628532 | ||
| The transcriptional landscape of the yeast genome defined by RNA sequencing | Q24633693 | ||
| Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies | Q24658205 | ||
| A model of human phenylalanine metabolism in normal subjects and in phenylketonuric patients | Q24672434 | ||
| Distribution of major health risks: findings from the Global Burden of Disease study | Q24802507 | ||
| Personalized medicine and treatment approaches in hypertension: current perspectives | Q26751135 | ||
| Translating cancer genomes and transcriptomes for precision oncology | Q26777081 | ||
| Transformative Impact of Proteomics on Cardiovascular Health and Disease: A Scientific Statement From the American Heart Association | Q26801529 | ||
| Epigenetics of epithelial Na(+) channel-dependent sodium uptake and blood pressure regulation | Q26829745 | ||
| The emerging paradigm of network medicine in the study of human disease | Q27026041 | ||
| Genetic risk prediction in complex disease | Q27027720 | ||
| A Randomized Trial of Intensive versus Standard Blood-Pressure Control | Q27231406 | ||
| Integrated genomic analyses of ovarian carcinoma | Q27860518 | ||
| A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. | Q27860879 | ||
| Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies | Q28036762 | ||
| Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack | Q28190600 | ||
| Metabolic profiles of cancer cells | Q28269762 | ||
| Huntington's disease | Q28284355 | ||
| Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group | Q28328155 | ||
| Analysis of biomedical data with multilevel glyphs | Q28655935 | ||
| Genome-wide association study of blood pressure extremes identifies variant near UMOD associated with hypertension | Q29417122 | ||
| Network medicine: a network-based approach to human disease | Q29547462 | ||
| The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity | Q29547693 | ||
| General cardiovascular risk profile for use in primary care: the Framingham Heart Study | Q29614189 | ||
| Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia | Q29614659 | ||
| Replication validity of genetic association studies | Q29615456 | ||
| Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma | Q29616862 | ||
| 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) | Q29617334 | ||
| Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients | Q29619542 | ||
| Precision medicine in cardiology | Q30249224 | ||
| Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association | Q30359686 | ||
| Single-molecule sequencing of an individual human genome | Q30434015 | ||
| Changes in the Geographic Patterns of Heart Disease Mortality in the United States: 1973 to 2010. | Q30744684 | ||
| Blood pressure levels and control in Italy: comprehensive analysis of clinical data from 2000-2005 and 2005-2011 hypertension surveys | Q30891449 | ||
| Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics | Q37130316 | ||
| A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers | Q37158337 | ||
| Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide | Q37192199 | ||
| Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine | Q37199477 | ||
| C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. | Q37363683 | ||
| Assessing the clinical utility of diagnostics used in drug therapy | Q37803526 | ||
| Pharmacometabonomics as an effector for personalized medicine. | Q37822760 | ||
| Angiotensin II and the vascular phenotype in hypertension | Q37859447 | ||
| The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? | Q37892929 | ||
| The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure | Q37936785 | ||
| Genetic biomarkers of hypertension and future challenges integrating epigenomics | Q38046386 | ||
| Genetic and molecular aspects of hypertension | Q38376301 | ||
| High-resolution characterization of a hepatocellular carcinoma genome | Q31005512 | ||
| Translational and emerging clinical applications of metabolomics in cardiovascular disease diagnosis and treatment | Q31082889 | ||
| Polymorphism in NEDD4L is associated with increased salt sensitivity, reduced levels of P-renin and increased levels of Nt-proANP. | Q33284000 | ||
| Post-translational modifications of the cardiac proteome in diabetes and heart failure | Q33361067 | ||
| High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis | Q33659414 | ||
| Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people | Q33701171 | ||
| Pharmacogenetics of antihypertensive treatment: detailing disciplinary dissonance | Q33776918 | ||
| Is high blood pressure a late manifestation of the hypertension syndrome? | Q33808255 | ||
| Systems biology: personalized medicine for the future? | Q33824947 | ||
| Type 2 diabetes risk alleles demonstrate extreme directional differentiation among human populations, compared to other diseases | Q34031536 | ||
| Impact of high-normal blood pressure on the risk of cardiovascular disease | Q34109606 | ||
| Gene-gene and gene-environmental interactions of childhood asthma: a multifactor dimension reduction approach. | Q34166205 | ||
| Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations | Q34248736 | ||
| Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor | Q34258285 | ||
| 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). | Q34351265 | ||
| Association of NEDD4L ubiquitin ligase with essential hypertension | Q34443485 | ||
| Endothelial dysfunction and stroke | Q34506201 | ||
| Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project | Q34534248 | ||
| Treatment of hypertension in patients 80 years of age or older | Q34766135 | ||
| Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions | Q35033003 | ||
| Bioinformatics challenges for personalized medicine | Q35051893 | ||
| Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs | Q35088179 | ||
| Vascular inflammation and endothelial dysfunction in experimental hypertension. | Q35207893 | ||
| Integrated metabolomics and genomics: systems approaches to biomarkers and mechanisms of cardiovascular disease | Q35534297 | ||
| Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC) | Q35773156 | ||
| Expression-based genome-wide association study links the receptor CD44 in adipose tissue with type 2 diabetes | Q35935710 | ||
| Ischemic Heart Disease Worldwide, 1990 to 2013: Estimates From the Global Burden of Disease Study 2013. | Q36108375 | ||
| Identification of Hypertension Predictors and Application to Hypertension Prediction in an Urban Han Chinese Population: A Longitudinal Study, 2005-2010. | Q36330766 | ||
| Metabolomics-based systems biology and personalized medicine: moving towards n = 1 clinical trials? | Q36630007 | ||
| Hypertension pharmacogenomics: in search of personalized treatment approaches | Q36652960 | ||
| Overcoming the dynamic range problem in mass spectrometry-based shotgun proteomics | Q36689095 | ||
| Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. | Q36738148 | ||
| The biological impact of mass-spectrometry-based proteomics | Q37030528 | ||
| The predictive capacity of personal genome sequencing | Q37090585 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 22 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | blood pressure | Q82642 |
| antihypertensive drug | Q575890 | ||
| personalized medicine | Q2072214 | ||
| arterial hypertension | Q41861 | ||
| precision medicine | Q17075943 | ||
| patient selection | Q17092352 | ||
| biomedical investigative technique | Q66648976 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 2671-2685 | |
| P577 | publication date | 2017-11-06 | |
| 2017-11-15 | |||
| P1433 | published in | Clinical Science | Q372419 |
| P1476 | title | Personalized medicine-a modern approach for the diagnosis and management of hypertension | |
| P478 | volume | 131 |
Search more.